Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inactivating LATS2 variation drives tumor progression and resistance to anti-PD-1 therapy in intrahepatic cholangiocarcinoma.

Clinical and molecular hepatology - 1 Jul 2026

Xu Ye, Liu Kai-Xuan, Wang Xin-Yu, Chen Shuang-Yi, Ye Yu-Hang, Li Ning, Weng Fan, Chen Long, Tu Cun-Yang, Tian Zi-Han, Luo Chu-Bin, Hu Zhi-Qiang, Zhou Zheng-Jun, Fan Jia, Zhou Jian, Zhou Shao-Lai

Abstract excerpt

BACKGROUND/AIMS: Recurrence is a major factor limiting the long-term survival of patients with intrahepatic cholangiocarcinoma (ICC). The molecular characteristics and potential therapeutic targets in ICC remain largely undefined. METHODS: Following our previous whole-exome sequencing study, we performed targeted sequencing, Sanger sequencing, and quantitative PCR to assess all coding exons and copy number...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Hippo Signaling Pathway

Share to Immune Checkpoint Inhibitors

Share to Kaplan-Meier Estimate

Share to Programmed Cell Death 1 Receptor

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41846519
DOI: 10.3350/cmh.2025.0997
PMCID: PMC13430327

Genes

LATS2
CCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inactivating LATS2 variation drives tumor progression and resistance to anti-PD-1 therapy in intrahepatic cholangiocarcinoma.PMID 41846519Read ↗

Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.Semantic proximity Read ↗

Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver.Semantic proximity Read ↗

Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.Semantic proximity Read ↗

HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.Semantic proximity Read ↗

CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinomaSemantic proximity Read ↗

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics AnalysisSemantic proximity Read ↗

The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations.Semantic proximity Read ↗

Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.Semantic proximity Read ↗

Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.